STOCK TITAN

[Form 4] CLOVER HEALTH INVESTMENTS, CORP. /DE Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Karen M. Soares, General Counsel & Secretary of Clover Health Investments (CLOV), reported a transaction dated 09/15/2025 in which 6,403 shares of Class A common stock were withheld to cover tax obligations upon vesting of 6.25% of the RSUs originally granted on 09/15/2022. The report shows the shares were disposed at a price of $3.14 and that the reporting person beneficially owned 1,463,084 shares following the transaction. The filing notes the remaining RSUs vest quarterly in equal installments with a final vesting date of 09/15/2026. The Form 4 is signed by an attorney-in-fact for the reporting person on 09/17/2025.

Karen M. Soares, Consigliera Generale e Segretaria di Clover Health Investments (CLOV), ha riferito una transazione datata 15/09/2025 nella quale 6.403 azioni ordinarie di Classe A sono state trattenute per coprire obblighi fiscali al vesting del 6,25% delle RSU originariamente concesse il 15/09/2022. Il rapporto mostra che le azioni sono state dispose a un prezzo di $3,14 e che il soggetto segnalante possedeva beneficiariamente 1.463.084 azioni dopo la transazione. Il deposito indica che le RSU rimanenti vestono trimestralmente in rate uguali con una data di vesting finale del 15/09/2026. Il Form 4 è stato firmato da un procuratore in fact per il soggetto segnalante il 17/09/2025.

Karen M. Soares, Consejera General y Secretaria de Clover Health Investments (CLOV), informó de una transacción fechada el 15/09/2025 en la que se retuvieron 6.403 acciones ordinarias de Clase A para cubrir obligaciones fiscales al vesting del 6,25% de las RSU originalmente concedidas el 15/09/2022. El informe indica que las acciones se vendieron a un precio de $3,14 y que la persona que reporta poseía beneficiosamente 1.463.084 acciones tras la transacción. La presentación señala que las RSU restantes se adjudicarán de forma trimestral en cuotas iguales con una fecha de vesting final del 15/09/2026. El Formulario 4 está firmado por un apoderado legal en nombre de la persona reportante el 17/09/2025.

Karen M. Soares, Clover Health Investments (CLOV)의 일반 변호사 겸 서기, 2025년 9월 15일자로 날짜가 기재된 거래를 보고했습니다. 이 거래에서 6.25%의 RSU가 vesting될 때의 세금 의무를 충당하기 위해 Class A 보통주 6,403주가 보류되었습니다. 보고서는 주식이 $3.14의 가격으로 처분되었고 보고 대상자는 거래 후 1,463,084주를 실제로 보유했다고 명시합니다. 제출서는 남은 RSU가 분기별로 동일한 금액으로 vest되며 최종 vesting 날짜가 2026-09-15이라고 밝힙니다. Form 4는 보고 대상자를 대신해 대리인에 의해 2025년 9월 17일에 서명되었습니다.

Karen M. Soares, Avocate générale et Secrétaire de Clover Health Investments (CLOV), a rapporté une transaction datée du 15/09/2025 selon laquelle 6 403 actions ordinaires de Classe A ont été retenues pour couvrir les obligations fiscales lors du vesting de 6,25 % des RSU initialement accordées le 15/09/2022. Le rapport indique que les actions ont été disposées à un prix de $3,14 et que la personne détenant l’information détenait avantageusement 1 463 084 actions après la transaction. Le dépôt indique que les RSU restantes vestent trimestriellement en versements égaux avec une date de vesting finale au 15/09/2026. Le Formulaire 4 est signé par un mandataire pour la personne déclarant le 17/09/2025.

Karen M. Soares, General Counsel & Secretary von Clover Health Investments (CLOV), meldete eine Transaktion vom 15.09.2025, bei der 6.403 Class-A-Stammaktien zurückbehalten wurden, um Steuerverpflichtungen beim Vesting von 6,25% der RSUs zu decken, die ursprünglich am 15.09.2022 gewährt wurden. Der Bericht zeigt, dass die Aktien zu einem Preis von $3,14 veräußert wurden und dass die meldepflichtige Person nach der Transaktion rechtlich besitzt 1.463.084 Aktien. Die Einreichung vermerkt, dass die verbleibenden RSU vierteljährlich in gleichen Raten vesten, mit einem endgültigen Vesting-Termin am 15.09.2026. Das Formular 4 ist am 17.09.2025 von einem Bevollmächtigten im Namen der meldepflichtigen Person unterschrieben.

Karen M. Soares، المستشار العام وكاتب السر في Clover Health Investments (CLOV)، ذكرت معاملة بتاريخ 15/09/2025 والتي تم فيها حجز 6,403 أسهم عادية من الفئة A لتغطية الالتزامات الضريبية عند vesting لـ 6.25% من RSU الممنوحة في 15/09/2022. يبين التقرير أن الأسهم بيعت بسعر $3.14 وأن الشخص المبلّغ امتلك فعلياً 1,463,084 سهماً بعد المعاملة. تشير الإيداع إلى أن RSU المتبقية ستفVest ربعياً دفعات متساوية مع تاريخ vesting نهائي في 2026-09-15. Form 4 موقّع من وكيل نيابة عن الشخص المبلّغ في 2025-09-17.

Karen M. Soares,Clover Health Investments(CLOV)的总法律顾问兼秘书,报告了一笔日期为2025-09-15的交易,其中为覆盖在触发6.25%之RSU原始授予日为2022-09-15的RSU vesting所产生的税务义务,扣留了6,403股A类普通股。 报告显示这些股票以每股$3.14的价格处置,且该报告人交易后实际持有1,463,084股。提交指出剩余RSU将按季度等额 vest,最终 vesting 日期为 2026-09-15Form 4 由代表报告人的代理人在 2025-09-17签署。

Positive
  • Vesting schedule disclosed — remaining RSUs vest quarterly in equal installments with final vesting on 09/15/2026.
  • Post-transaction ownership reported — reporting person beneficially owned 1,463,084 Class A shares following the transaction.
Negative
  • Shares withheld — 6,403 Class A shares were disposed to cover tax obligations.
  • Disposition recorded — transaction coded as a disposition (F) at a price of $3.14 per share.

Insights

TL;DR: Routine tax withholding on RSU vesting disclosed; vesting schedule and post-transaction ownership clearly reported.

The filing documents a standard administrative action: automatic withholding of 6,403 Class A shares to satisfy tax obligations related to RSU vesting. The company and reporting person disclosed the original grant date, the portion that vested (6.25%), and the remaining quarterly vesting through 09/15/2026, which supports transparency on insider equity remuneration. The post-transaction beneficial ownership figure of 1,463,084 shares is provided, enabling investors to track insider ownership levels.

TL;DR: Non-material insider disposition for tax withholding; transaction details and remaining vesting cadence are explicitly stated.

The transaction is coded as a disposition (code F) and reflects withholding at a price of $3.14 for 6,403 shares. This is a mechanical tax-related disposition rather than a voluntary sale for liquidity. The clear disclosure of the remaining vesting schedule through 09/15/2026 and the exact post-transaction share count allows straightforward reconciliation with outstanding equity awards and insider ownership metrics.

Karen M. Soares, Consigliera Generale e Segretaria di Clover Health Investments (CLOV), ha riferito una transazione datata 15/09/2025 nella quale 6.403 azioni ordinarie di Classe A sono state trattenute per coprire obblighi fiscali al vesting del 6,25% delle RSU originariamente concesse il 15/09/2022. Il rapporto mostra che le azioni sono state dispose a un prezzo di $3,14 e che il soggetto segnalante possedeva beneficiariamente 1.463.084 azioni dopo la transazione. Il deposito indica che le RSU rimanenti vestono trimestralmente in rate uguali con una data di vesting finale del 15/09/2026. Il Form 4 è stato firmato da un procuratore in fact per il soggetto segnalante il 17/09/2025.

Karen M. Soares, Consejera General y Secretaria de Clover Health Investments (CLOV), informó de una transacción fechada el 15/09/2025 en la que se retuvieron 6.403 acciones ordinarias de Clase A para cubrir obligaciones fiscales al vesting del 6,25% de las RSU originalmente concedidas el 15/09/2022. El informe indica que las acciones se vendieron a un precio de $3,14 y que la persona que reporta poseía beneficiosamente 1.463.084 acciones tras la transacción. La presentación señala que las RSU restantes se adjudicarán de forma trimestral en cuotas iguales con una fecha de vesting final del 15/09/2026. El Formulario 4 está firmado por un apoderado legal en nombre de la persona reportante el 17/09/2025.

Karen M. Soares, Clover Health Investments (CLOV)의 일반 변호사 겸 서기, 2025년 9월 15일자로 날짜가 기재된 거래를 보고했습니다. 이 거래에서 6.25%의 RSU가 vesting될 때의 세금 의무를 충당하기 위해 Class A 보통주 6,403주가 보류되었습니다. 보고서는 주식이 $3.14의 가격으로 처분되었고 보고 대상자는 거래 후 1,463,084주를 실제로 보유했다고 명시합니다. 제출서는 남은 RSU가 분기별로 동일한 금액으로 vest되며 최종 vesting 날짜가 2026-09-15이라고 밝힙니다. Form 4는 보고 대상자를 대신해 대리인에 의해 2025년 9월 17일에 서명되었습니다.

Karen M. Soares, Avocate générale et Secrétaire de Clover Health Investments (CLOV), a rapporté une transaction datée du 15/09/2025 selon laquelle 6 403 actions ordinaires de Classe A ont été retenues pour couvrir les obligations fiscales lors du vesting de 6,25 % des RSU initialement accordées le 15/09/2022. Le rapport indique que les actions ont été disposées à un prix de $3,14 et que la personne détenant l’information détenait avantageusement 1 463 084 actions après la transaction. Le dépôt indique que les RSU restantes vestent trimestriellement en versements égaux avec une date de vesting finale au 15/09/2026. Le Formulaire 4 est signé par un mandataire pour la personne déclarant le 17/09/2025.

Karen M. Soares, General Counsel & Secretary von Clover Health Investments (CLOV), meldete eine Transaktion vom 15.09.2025, bei der 6.403 Class-A-Stammaktien zurückbehalten wurden, um Steuerverpflichtungen beim Vesting von 6,25% der RSUs zu decken, die ursprünglich am 15.09.2022 gewährt wurden. Der Bericht zeigt, dass die Aktien zu einem Preis von $3,14 veräußert wurden und dass die meldepflichtige Person nach der Transaktion rechtlich besitzt 1.463.084 Aktien. Die Einreichung vermerkt, dass die verbleibenden RSU vierteljährlich in gleichen Raten vesten, mit einem endgültigen Vesting-Termin am 15.09.2026. Das Formular 4 ist am 17.09.2025 von einem Bevollmächtigten im Namen der meldepflichtigen Person unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Soares Karen

(Last) (First) (Middle)
C/O CLOVER HEALTH INVESTMENTS, CORP.
NOT APPLICABLE

(Street)
WILMINGTON DE 19801

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel & Secretary
3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 09/15/2025 F 6,403(1) D $3.14 1,463,084 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations upon the vesting, on September 15, 2025, of 6.25% of the original number of time-based restricted stock units ("RSUs") granted to the Reporting Person on September 15, 2022. The remaining RSUs vest quarterly in equal installments of 6.25%, with a final vesting date occurring on September 15, 2026, subject to the continued service of the Reporting Person on each such vesting date.
Remarks:
/s/Peter J. Rivas as attorney-in-fact for Karen M. Soares 09/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Karen M. Soares (CLOV) report on the Form 4?

The Form 4 reports that 6,403 Class A shares were withheld to cover tax obligations upon RSU vesting on 09/15/2025.

How many shares did the reporting person own after the transaction?

The filing states the reporting person beneficially owned 1,463,084 Class A shares following the reported transaction.

What was the price used for the withheld shares?

The shares were recorded at a price of $3.14 per share.

What portion of the RSU grant vested and what is the remaining vesting schedule?

The filing states 6.25% of the original RSU grant vested on 09/15/2025; the remaining RSUs vest quarterly in equal installments with final vesting on 09/15/2026.

When was the Form 4 signed and by whom?

The Form 4 was signed on 09/17/2025 by an attorney-in-fact, Peter J. Rivas, for Karen M. Soares.
Clover Health Investments Corp

NASDAQ:CLOV

CLOV Rankings

CLOV Latest News

CLOV Latest SEC Filings

CLOV Stock Data

1.65B
403.66M
3.88%
35.27%
9.43%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States
JERSEY CITY